Ozempic, Wegovy, and Mounjaro Week by Week: What to Actually Expect
A week-by-week breakdown of GLP-1 side effects, energy, and appetite changes — from week 1 nausea to week 12 plateaus. Know what's normal at each stage.
If you've searched "is this normal" more than once since starting a GLP-1 medication, you're not alone. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) both cause side effects that shift significantly depending on where you are in treatment — but most information online treats "GLP-1 side effects" as one static list, when in reality week 3 and week 12 can feel like completely different experiences.
Here's a realistic breakdown of what tends to happen at each stage, and why.
Week 1–2: Adjustment
Your body is meeting the medication for the first time. GLP-1 receptor agonists slow gastric emptying — food stays in your stomach longer, which is the mechanism behind both the appetite suppression and the early nausea. Mild to moderate nausea, some fullness after small meals, and occasional fatigue are common. Energy dips are normal here; your body is recalibrating how it processes food and signals hunger.
What helps: smaller, more frequent meals; avoiding high-fat or greasy food (it sits longer and can worsen nausea); staying upright for 30–60 minutes after eating.
Week 3–4: Peak side effects
For most people on a starting or early dose, this is when nausea tends to peak. It's also frequently the point where people are most tempted to stop — worth knowing in advance that this is often the hardest stretch, not a sign that something is wrong.
Protein intake often drops during this window because appetite is low and nausea makes eating feel effortful. This matters more than most people realize: without deliberate protein intake, weight loss during this phase can come disproportionately from muscle rather than fat.
Week 5–8: Dose increases
If you're on a titration schedule, doses often step up around this window (varies by medication and prescriber). Side effects can briefly resurface with each increase — treat it like a mini-restart of weeks 1–3: smaller portions, protein first, patience.
Week 8–12: Plateaus
Weight loss frequently slows or briefly stalls in this range, even when everything is being done "right." This is a normal part of the process, not a sign that the medication has stopped working — but it's also the point where tracking (rather than guessing) becomes most valuable. A flat week with low protein intake tells a very different story than a flat week with strong, consistent protein.
Week 12+: Maintenance patterns emerge
By this point, most people have a sense of their baseline appetite, tolerable meal sizes, and symptom patterns. This is a good checkpoint to reassess: is protein intake sustainable long-term? Is muscle being preserved alongside fat loss? These questions matter more the longer therapy continues.
The pattern across all of this
Nearly every phase above has the same two threads running through it: appetite suppression makes it harder to hit protein targets, right when protein matters most for preserving muscle — and knowing what's normal for your specific week reduces the anxiety that leads people to second-guess or discontinue treatment unnecessarily.
That's the entire premise behind week-specific tracking instead of generic advice. A nausea score of 6/10 in week 3 and a nausea score of 6/10 in week 10 usually call for different responses — one is often expected and short-term, the other may be worth a conversation with your prescriber.
This article is educational and not a substitute for medical advice. Individual experiences with GLP-1 medications vary significantly — always consult your prescriber about symptoms, dose adjustments, or concerns specific to your treatment.
Not medical advice. Always consult your healthcare provider.